JP7831775B2 - 新生血管形成因子を阻害するための化合物およびその用途 - Google Patents

新生血管形成因子を阻害するための化合物およびその用途

Info

Publication number
JP7831775B2
JP7831775B2 JP2022536658A JP2022536658A JP7831775B2 JP 7831775 B2 JP7831775 B2 JP 7831775B2 JP 2022536658 A JP2022536658 A JP 2022536658A JP 2022536658 A JP2022536658 A JP 2022536658A JP 7831775 B2 JP7831775 B2 JP 7831775B2
Authority
JP
Japan
Prior art keywords
neovascular
compound
neovascularization
case
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022536658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506838A (ja
JP2023506838A5 (https=
Inventor
ビョンヒョン カン
ソヨン キム
ナムグ ユン
チャンウク イ
ドンホ パク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smartin Bio Inc
Original Assignee
Smartin Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smartin Bio Inc filed Critical Smartin Bio Inc
Publication of JP2023506838A publication Critical patent/JP2023506838A/ja
Publication of JP2023506838A5 publication Critical patent/JP2023506838A5/ja
Application granted granted Critical
Publication of JP7831775B2 publication Critical patent/JP7831775B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022536658A 2019-12-16 2020-12-16 新生血管形成因子を阻害するための化合物およびその用途 Active JP7831775B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2019-0168238 2019-12-16
KR20190168238 2019-12-16
PCT/KR2020/018475 WO2021125800A1 (ko) 2019-12-16 2020-12-16 신생혈관형성인자의 억제를 위한 화합물 및 그 용도

Publications (3)

Publication Number Publication Date
JP2023506838A JP2023506838A (ja) 2023-02-20
JP2023506838A5 JP2023506838A5 (https=) 2023-12-20
JP7831775B2 true JP7831775B2 (ja) 2026-03-17

Family

ID=76477859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022536658A Active JP7831775B2 (ja) 2019-12-16 2020-12-16 新生血管形成因子を阻害するための化合物およびその用途

Country Status (9)

Country Link
US (1) US12545695B2 (https=)
EP (1) EP4079309A4 (https=)
JP (1) JP7831775B2 (https=)
KR (1) KR20210076875A (https=)
CN (1) CN114901290B (https=)
AU (1) AU2020409912A1 (https=)
BR (1) BR112022011147A2 (https=)
CA (1) CA3164800A1 (https=)
WO (1) WO2021125800A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901290B (zh) 2019-12-16 2024-09-03 蔚山科学技术院 抑制血管新生因子的化合物及其用途
JP7766885B2 (ja) * 2021-06-15 2025-11-11 スマーティン バイオ インコーポレイテッド Ｔｒａｐ１阻害剤およびその用途
KR102894216B1 (ko) * 2022-12-15 2025-12-18 울산과학기술원 Trap-1 억제제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012524074A (ja) 2009-04-17 2012-10-11 コルビー ファーマシューティカル カンパニー 酸化的ストレスモジュレーター（ｏｓｍ）を含む薬学的に活性な組成物、新規化学物質、組成物および用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20060229278A1 (en) 1998-11-25 2006-10-12 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
NZ513547A (en) * 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
JP4648319B2 (ja) 2003-08-22 2011-03-09 アンティポディーン ファーマシューティカルズ インコーポレイティド ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
KR20070030815A (ko) 2004-07-13 2007-03-16 오리디스 비오메드 포르슝스-운트 엔트비크룽스 게엠베하 간질환 및 상피암의 치료에서 미토콘드리아적으로 표적화된산화방지제의 용도
US7750018B2 (en) 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
KR101621418B1 (ko) 2014-03-19 2016-05-23 울산과학기술원 미토콘드리아 표적화된 항-종양 조성물
CN114901290B (zh) 2019-12-16 2024-09-03 蔚山科学技术院 抑制血管新生因子的化合物及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012524074A (ja) 2009-04-17 2012-10-11 コルビー ファーマシューティカル カンパニー 酸化的ストレスモジュレーター（ｏｓｍ）を含む薬学的に活性な組成物、新規化学物質、組成物および用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ORTEGA,M.J. et al.，5-Alkylresorcinol derivatives from the bryozoan Schizomavella mamillata: isolation, synthesis, and antioxidant activity，Marine Drugs，2017年，Vol.15, No.11，p.344/1-344/17
STN International，file REGISTRY [online]，[令和６年１０月２５日検索]，掲載日：～２０１６年１０月２６日, CAS Registry No. 2020059-16-7の化合物を始め全化合物
YAO,F. et al.，Development of novel tail-modified anandamide analogs，Bioorganic & Medicinal Chemistry Letters，2008年，Vol.18, No.22，p.5912-5915

Also Published As

Publication number Publication date
WO2021125800A1 (ko) 2021-06-24
AU2020409912A1 (en) 2022-06-16
EP4079309A1 (en) 2022-10-26
CN114901290A (zh) 2022-08-12
US12545695B2 (en) 2026-02-10
KR20210076875A (ko) 2021-06-24
CA3164800A1 (en) 2021-06-24
US20230088747A1 (en) 2023-03-23
EP4079309A4 (en) 2024-01-10
JP2023506838A (ja) 2023-02-20
CN114901290B (zh) 2024-09-03
BR112022011147A2 (pt) 2022-08-23

Similar Documents

Publication Publication Date Title
AU2021201332B2 (en) Compositions and methods of modulating short-chain dehydrogenase activity
JP7831775B2 (ja) 新生血管形成因子を阻害するための化合物およびその用途
JP2021054856A (ja) トリアジン化合物及びその医薬用途
EP3215155A1 (en) Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase
JP2019524749A (ja) 神経新生の促進及びニュ−ロン細胞死の阻害のための短鎖脱水素酵素活性の阻害剤
CA2928867A1 (en) Substituted oxopyridine derivatives
TWI324066B (en) A pharmaceutical composition for inhibiting cell migration induced by an angiogenic factor
CZ292092A3 (en) Tricyclic heterocyclic compounds
JP2020193235A (ja) ヒドロキシトリアジン化合物及びその医薬用途
WO2021213518A1 (zh) 用于预防或治疗脂质代谢相关疾病的化合物
JP2023546742A (ja) Ｌｐａ受容体活性に付随する症状を治療するための化合物および組成物
WO2019178383A1 (en) Inhibition of bmp signaling, compounds, compositions and uses thereof
WO2024112895A1 (en) Compounds and compositions for treating conditions associated with lpa receptor activity
JP7696301B2 (ja) タンパク質分解のための化合物、組成物、および方法
JP2009522363A (ja) プロテインキナーゼの阻害剤
US20030229113A1 (en) Keratinocyte growth inhibitors and hydroxamic acid derivatives
JP7834361B2 (ja) 置換４－（［１，２，４］トリアゾロ［１，５－ａ］ピリジン－６－イル）チオフェン－２－カルボキサミド誘導体及びその使用
US20240400562A1 (en) Compounds and compositions for treating conditions associated with lpa receptor activity
CN117769559A (zh) Trap1抑制剂及其用途
JP7766885B2 (ja) Ｔｒａｐ１阻害剤およびその用途
WO2014158302A1 (en) Novel sphingosine 1-phosphate receptor antagonists
KR102701383B1 (ko) 리포-하이드록삼산 유도체 및 이의 약학적 용도
JPWO2014157727A1 (ja) 眼疾患治療剤
JP5476650B2 (ja) 新規ｄｉｆ−１誘導体
KR20220167944A (ko) Trap-1 억제제의 안과질환 치료 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260225

R150 Certificate of patent or registration of utility model

Ref document number: 7831775

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150